Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Olivier Rixe"'
Autor:
Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd Bauer, David Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke
Publikováno v:
Clin Cancer Res
Purpose: TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor−related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in combination with gemcitabine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60473b0d4d51a50755b6880e00e30770
https://europepmc.org/articles/PMC9475244/
https://europepmc.org/articles/PMC9475244/
Autor:
Anthony J. Olszanski, Patrick M. Forde, Olivier Rixe, Yanyan Lou, Asha Nayak-Kapoor, David S. Hong, Vi K. Chiu, Floyd Fox, Margaret A. Marshall, Agron Collaku, Tomislav Dragovich, Rom Leidner, James N. Atkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)
Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolu
Autor:
Olivier Rixe, Anthony J. Olszanski, Ken Ogasawara, Maria Palmisano, Jian Yin, Christine Xu, Gopal Krishna, Patricia LoRusso
Publikováno v:
Cancer chemotherapy and pharmacology. 86(1)
Fedratinib, an oral selective kinase inhibitor with activity against both wild type and mutationally activated Janus kinase 2, has been approved for the treatment of adult patients with intermediate-2 or high-risk myelofibrosis by the US Food and Dru
Autor:
Xavier Paliard, Olivier Rixe
Publikováno v:
Targeted Oncology
The clinical development of cancer drugs is rapidly moving from empirical "one drug fits all" or development-by-tumor-type approaches towards more personalized treatment models. A deeper understanding of cancer and the immune system, novel technologi
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
Autor:
Olivier Rixe, F. Meiring Nortier, Mehran Makvandi, Sam Simon, Jonathan W. Engle, Jeffrey P. Norenberg, Robert W. Atcher, Michael E. Fassbender, Edouard Dupis, Kevin D. John, Eva R. Birnbaum
Publikováno v:
Targeted Oncology. 13:189-203
Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nan
Autor:
Anthony J. Olszanski, Olivier Rixe, Olugbenga Olowokure, Séverine Doroumian, John C. Morris, Jian Y. Yin, Roger B. Cohen, Liji Shen, Igor Puzanov, Patricia LoRusso
Publikováno v:
Anti-Cancer Drugs
Supplemental Digital Content is available in the text.
Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study (NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT
Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study (NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT
Autor:
Laurent Kassalow, Jean François Dedieu, Monica M. Mita, John C. Morris, James L. Wade, John Sarantopoulos, Claudine Wack, Alain C. Mita, A. Craig Lockhart, Olivier Rixe
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:1113-1124
Cabazitaxel is primarily metabolized by CYP3A. This study evaluated the impact of moderate/strong CYP3A inhibitors [aprepitant (Study Part 2); ketoconazole (Study Part 3)] or strong CYP3A inducers [rifampin (Study Part 4)] on the pharmacokinetics of
Autor:
El Mustapha Bahassi, Li Deng, Keith M. Wilson, Trisha Wise-Draper, Jiang Wang, Susanne I. Wells, Colleen N. Darnell, Olivier Rixe, Peter J. Stambrook, Ya-Qin Li
Publikováno v:
European Journal of Cancer. 49:2345-2355
Background Cetuximab is an epidermal growth factor receptor (EGFR)-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer, but no predictive biomarker
Autor:
B. Billemont, Eric Van Cutsem, David Khayat, Karen Soussan-Lazard, Sylvaine Cartot-Cotton, Olivier Rixe, Sabine Tejpar, Jean-Baptiste Meric, Sylvie Assadourian, Chris Verslype
Publikováno v:
European Journal of Cancer. 49:17-24
Background To determine dose-limiting toxicities (DLTs), recommended phase II trial dose (RPTD), safety, preliminary antitumour activity and pharmacokinetics of intravenous aflibercept with irinotecan, 5-fluorouracil and leucovorin (LV5FU2). Patients
Autor:
David I. Quinn, Pierre François Clot, Jian Yin, James L. Wade, A. Craig Lockhart, James W. Mier, Wenping Zhang, John Sarantopoulos, Alain C. Mita, John C. Morris, Aiwu He, Olivier Rixe, Jimmy J. Hwang, Chung-Tsen Hsueh, Claudine Wack
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Cabazitaxel has not been studied in patients with hepatic impairment (HI). This phase I study assessed cabazitaxel safety and pharmacokinetics in patients with HI. Methods Patients with advanced, non-hematologic cancer, and normal hepatic fun